[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TLR5

Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF13855 Leucine rich repeat
PF01582 TIR domain
Function

Participates in the innate immune response to microbial agents. Mediates detection of bacterial flagellins. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006809 nitric oxide biosynthetic process
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009306 protein secretion
GO:0009612 response to mechanical stimulus
GO:0031349 positive regulation of defense response
GO:0032496 response to lipopolysaccharide
GO:0032637 interleukin-8 production
GO:0032677 regulation of interleukin-8 production
GO:0032757 positive regulation of interleukin-8 production
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034123 positive regulation of toll-like receptor signaling pathway
GO:0034146 toll-like receptor 5 signaling pathway
GO:0042742 defense response to bacterium
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045137 development of primary sexual characteristics
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0046209 nitric oxide metabolic process
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0048608 reproductive structure development
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050829 defense response to Gram-negative bacterium
GO:0061458 reproductive system development
GO:0071214 cellular response to abiotic stimulus
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071260 cellular response to mechanical stimulus
GO:0071396 cellular response to lipid
GO:0071496 cellular response to external stimulus
GO:0072593 reactive oxygen species metabolic process
GO:0098542 defense response to other organism
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1904407 positive regulation of nitric oxide metabolic process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0005126 cytokine receptor binding
GO:0005149 interleukin-1 receptor binding
GO:0070851 growth factor receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-5603037: IRAK4 deficiency (TLR5)
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-5602680: MyD88 deficiency (TLR5)
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TLR5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TLR5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26831100Colorectal CarcinomaPromote immunityToll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
19620771Ovarian CarcinomaPromote immunityHere we demonstrated that linear polyethylenimine-based (PEI-based) nanoparticles encapsulating siRNA were preferentially and avidly engulfed by regulatory DCs expressing CD11c and programmed cell death 1-ligand 1 (PD-L1) at ovarian cancer locations in mice. PEI triggered robust and selective TLR5 activation in vitro and elicited the production of hallmark TLR5-inducible cytokines in WT mice, but not in Tlr5-/- littermates. Our results demonstrate that the intrinsic TLR5 and TLR7 stimulation of siRNA-PEI nanoparticles synergizes with the gene-specific silencing activity of siRNA to transform tumor-infiltrating regulatory DCs into DCs capable of promoting therapeutic antitumor immunity.
21427357Breast CarcinomaPromote immunityActivation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. These findings indicate that TLR5 activation by flagellin mediates innate immune response to elicit potent antitumor activity in breast cancer cells themselves, which may serve as a novel therapeutic target for human breast cancer therapy.
20483744Prostate CarcinomaPromote immunityOverall, these data show for the first time that TLR3 and TLR5 stimulation of human prostate cancer cells triggers the production of chemokines, which, in turn, favor the attraction of immune effectors, thereby representing a tool to enhance the efficacy of conventional therapies by stimulating anticancer immune responses.
25223833melanomaPromote immunityTaken together, our results report a new immunotherapeutic approach based on TLR-5 activation and IFN-gamma production capable to control the metastatic growth of B16F10-Nex2 melanoma, being a promising alternative to be associated with chemotherapeutic drugs for an effective anti-tumor responses.
21804019lymphoma; lung carcinoma; colon carcinomaPromote immunityWe demonstrate that human monocyte-derived DCs are endowed with significant cytotoxic activity against tumor cells following activation with LPS. The mechanism of DC-mediated tumor cell killing primarily involves peroxynitrites. This observed cytotoxic activity is restricted to immature DCs. Additionally, after killing, these cytotoxic DCs are able to activate tumor Ag-specific T cells
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TLR5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TLR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3330.212
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4230.426
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2690.531
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5010.172
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8050.564
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1190.945
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3910.292
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8910.315
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2190.834
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6240.553
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5540.267
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3580.00653
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TLR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TLR5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TLR5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TLR5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TLR5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TLR5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TLR5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTLR5
Nametoll-like receptor 5
Aliases TIL3; MGC126430; MGC126431; Toll/interleukin-1 receptor-like protein 3; SLEB1; systemic lupus erythematosus ......
Chromosomal Location1q32.3-q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TLR5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.